Samsung BioLogics' New Plant Approved by FDA

Samsung BioLogics, a Korean biologics CMO, received US FDA approval to produce an antibody drug substance at its second plant. The second facility, currently Samsung's largest, was completed in March 2016. Samsung has a larger $740 million third plant scheduled to complete its construction by the end of this year. The company has two divisions: a biologics CMO and Bioepis, a joint venture with Biogen that makes biosimilars. In 2016, Samsung completed a $2 billion IPO in South Korea . More details.... Stock Symbols: (KRX: 207940) (NSDQ: BIIB) Share this with colleagues: // //